Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492011 | 0.81 | LAP3 (0.48) | TSHRLAP3TDP1POLBTP53 | |
| SCHEMBL9723381 | 0.79 | TSHR (0.39) | TSHRTDP1POLBTP53GAA | |
| SCHEMBL27682034 | 0.75 | TSHR (0.39) | TSHRLAP3TDP1POLBTP53 | |
| SCHEMBL28659627 | 0.72 | TSHR (0.40) | TSHRLAP3TDP1POLBTP53 | |
| SCHEMBL4117495 | 0.72 | POLB (0.38) | TSHRPOLBGAAALDH1A1LMNA | |
| SCHEMBL10385714 | 0.71 | LAP3 (0.50) | TSHRLAP3TDP1POLBTP53 | |
| SCHEMBL282248 | 0.71 | TSHR (0.48) | TSHRLAP3TDP1POLBTP53 | |
| SCHEMBL7111165 | 0.69 | PPARD (0.43) | TSHRLAP3TDP1POLBTP53 | |
| SCHEMBL3122516 | 0.69 | LAP3 (0.48) | TSHRLAP3TP53CYP3A4 | |
| SCHEMBL3175484 | 0.69 | TSHR (0.46) | TSHRTDP1POLBTP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642339-B2 | Hepatitis C; 1-benzyloxycarbonylamino-2-vinyl-cyclopropyl)-phenyl-phosphinic acid ethyl ester | GILEAD SCIENCES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642339-B2 | Hepatitis C; 1-benzyloxycarbonylamino-2-vinyl-cyclopropyl)-phenyl-phosphinic acid ethyl ester | GILEAD SCIENCES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080311077-A1 | Antiviral Compounds | GILEAD SCIENCES, INC. | 2008-12-18 | — | — | US | disclosed |
| US-4946833-A | ANTITUMOR AGENTS | ADIR ET CIE (FR) | 1990-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311077-A1 | Antiviral Compounds | EIF2AK2, MAVS, ITPA | TSHR 4801/4885LAP3 1605/4885TDP1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.